Experimental nitric oxide-donating glaucoma treatment "effective", but Pfizer drops it

Article

PF-03187207, an experimental glaucoma treatment that was being developed by NicOx and Pfizer, has been shown in Phase II testing to be more effective in lowering IOP under certain circumstances than Pfizer's Xalatan (latanoprost) 0.005%, but it will not be advanced into Phase III testing, Pfizer has announced.

PF-03187207, an experimental glaucoma treatment that was being developed by NicOx and Pfizer, has been shown in Phase II testing to be more effective in lowering IOP under certain circumstances than Pfizer's Xalatan (latanoprost) 0.005%, but it will not be advanced into Phase III testing, Pfizer has announced.

The randomized, double-masked dose-finding study enrolled 215 patients with primary open-angle glaucoma or ocular hypertension in at least one eye. In one study arm, subjects were treated for 28 days with Xalatan 0.005% either in the morning or the evening. The remaining five study arms treated subjects - in the morning, evening or both - with various doses of PF-03187207, a nitric oxide-donating prostaglandin analogue. IOP was measured at baseline, again at 8am, 10am, 1pm and 4pm on day one, and again once a week thereafter, on days seven, 14, 21 and 28.

The Phase II trial, comparing safety and efficacy of Xalatan with PF-03187207, did not achieve its primary endpoint of clinically statistical significance of PF-03187207 over Xalatan: the difference achieved between the two treatments was found to be approximately 1 mmHg - a difference of only 12%. No serious adverse events were noted. However, evening dosing of PF-03187207 was found to produce a statistically significant improvement (1.4 mmHg; 22%) over evening administration of Xalatan.

Although the companies believe that the nitric oxide donation has proved to be beneficial, Pfizer and NicOx will not be proceeding to Phase III testing of PF-03187207. Follow-up compounds are now being developed. PF-03187207 is still in Phase II testing in Japan, and Pfizer has announced that it would consider registering the product in the Asian market, depending on the results of trials, which are expected in the third quarter of this year.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
© 2025 MJH Life Sciences

All rights reserved.